Figure 5 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

Alexander Muik; Elena Garralda; Işıl Altıntaş; Friederike Gieseke; Ravit Geva; Eytan Ben‐Ami; Corinne Maurice‐Dror; Emiliano Calvo; Patricia LoRusso; Guzmán Alonso; María E. Rodriguez-Ruiz; Kristina B. Schoedel; Jordan M. Blum; Bianca Sänger; Theodora W. Salcedo; Saskia M. Burm; Eliana Stanganello; Dennis Verzijl; Fulvia Vascotto; Angelica Sette; Juliane Quinkhardt; Theo S. Plantinga; Aras Toker; Edward N. van den Brink; Mark Fereshteh; Mustafa Diken; David Satijn; Sebastian Kreiter; Esther C.W. Breij; Gaurav Bajaj; Eleni Lagkadinou; Kate Sasser; Özlem Türeci; Ulf Forssmann; Tahamtan Ahmadi; Uğur Şahin; Maria Jure‐Kunkel; Ignacio Melero

doi:10.1158/2159-8290.30834194

Abstract

GEN1046 antitumor efficacy in patients with advanced solid tumors. A, Waterfall plot of best relative percent change from baseline in tumor size. B–E, CT over time (B and C) and plots of immunologic changes in the periphery (D and E) following the first dose of GEN1046 in a patient with metastatic NSCLC treated with 200 mg GEN1046 (B and D) and a patient with metastatic ovarian cancer treated with 80 mg GEN1046 (C and E). Numbers (percentages) below CT scans are sum of diameter of target lesion (percent change from baseline). NA, not applicable; NE, not evaluable. aArchival formalin-fixed paraffin-embedded block of tumor tissue obtained >5 years prior was evaluated; loss of PD-L1 immunoreactivity may have occurred.

Related Publications

Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study

Yanbin Chen , Chuanyong Mu , Jian‐An Huang

Aims and background The programmed death-1-ligand 1 (PD-L1) has been recently suggested to play a pivotal role in the immune evasion of tumors from host immune system. In the st...

2012 Tumori Journal 216 citations

68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer

Clemens Kratochwil , Paul Flechsig , Thomas Lindner +15 more

The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP i...

2019 Journal of Nuclear Medicine 1301 citations

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Seung Tae Kim , Răzvan Cristescu , Adam J. Bass +20 more

Clinical studies support the efficacy of programmed cell death 1 (PD-1) targeted therapy in a subset of patients with metastatic gastric cancer (mGC). With the goal of identifyi...

2018 Nature Medicine 1624 citations

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach , Nancy Zhang , Ellie Corigliano +7 more

A companion diagnostic assay was codeveloped by Dako for pembrolizumab non–small-cell lung cancer clinical trials to detect PD-L1 expression by immunohistochemistry (IHC). This ...

2016 Applied immunohistochemistry & molecu... 346 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer , Charles G. Drake , Ira Wollner +17 more

Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and ...

2010 Journal of Clinical Oncology 2881 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Figure 5 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Alexander Muik, 
                                
                                    Elena Garralda, 
                                
                                    Işıl Altıntaş
                                
                                et al.
                            
                            (2025). 
                            Figure 5 from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30834194

Identifiers

DOI: 10.1158/2159-8290.30834194